Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HEB, Hemispherx Biopharma (AMEX)NEW -- Ignore unavailable to you. Want to Upgrade?

To: Gerald Underwood who wrote (727)	12/15/1999 10:07:00 AM
From: LORD ERNIE	Read Replies (1) \| Respond to of 857

For the visitors of this thread: HEMISPHERX ANNOUNCES NEW APPROACH TO HIV-INHIBITION; TEST RESULTS SHOW POTENTIAL ADVANTAGES OF AMPLIGEN(R) AS ANTI-HIV AGENT PHILADELPHIA, Dec 15, 1999 /PRNewswire via COMTEX/ -- Hemispherx Biopharma, Inc. (Amex: HEB; HEBws) today announced that recent independent laboratory test results show potential advantages of its product Ampligen(R) as an anti-HIV agent. According to findings presented today at the Immune-Based Therapy-2 (IBT-2) conference in Boston, 12 out of 14 drugs approved by the Food and Drug Administration (FDA) as anti-HIV agents demonstrated pronounced antiviral effectiveness with Ampligen(R), with no examples of inhibiting the effectiveness of other drugs. Also, all members of the newest class of powerful HIV inhibitors, termed protease inhibitors, were enhanced by Ampligen. In fact, enhancement magnitudes varied from several hundred percent enhancement to more than 800% enhancement. The new results, developed by independent researchers at the University of California at Irvine, examined all 14 FDA-approved anti-HIV agents. IBT-2 is a clinical/research workshop sponsored by a group of nine AIDS service-and-research entities in the Boston area. The new test-tube studies examined various concentrations of the different drugs under conditions designed to simulate the clinical situation in patients. Using a pharmacological approach termed "Mixed Drug Effect Analyses," researchers determined whether a new drug addition dramatically increased antiviral effectiveness (known as drug synergy), had no effect whatsoever (known as neutral compound) or inhibited the effectiveness of the other drugs (known as drug antagonism). "Pronounced antiviral synergy represents a potentially new therapeutic approach to long-term suppression of HIV," said William A. Carter, Chairman and Chief Executive Officer of Hemispherx. "In recent years, powerful drug cocktails have subdued the virus to undetectable levels in many patients. But various studies have recently found that the virus comes roaring back in the majority of patients because the virus survived therapy by hiding in certain cells and tissues. Further intensification of antiretroviral treatment by therapies that are less toxic and complex are a promising avenue of investigation. Double-stranded RNA technology, which includes Ampligen(R), represents a mechanism of action distinctly different from that of the available 14 FDA-approved drugs." Hemispherx Biopharma, Inc. is a biopharmaceutical company specializing in new therapeutic approaches to HIV/AIDS, Chronic Fatigue Syndrome (CFS) and hepatitis B/C utilizing the immune system. It has offices in Philadelphia, Belgium and France and new drug development facilities in the Washington, D.C., area. Hemispherx was recently listed on the "Russell 2000" Index of small capitalization stocks. Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. sitors of this thread THE NEWS: